INSM: BRINSUPRI's blockbuster launch and robust pipeline set the stage for sustained, multi-year growth

BRINSUPRI's launch has exceeded expectations, with first-year revenue estimates of $1.25—$1.4 billion and peak sales guidance raised above $7 billion. Expansion into COPD/asthma comorbid populations and international markets, especially Japan, are key growth drivers. The pipeline, including TPIP an…